DNase I Solution
High-performance recombinant DNase I (10 mg/mL, ≥2,000 U/mg, Kunitz) for DNA removal in RNA workflows, free of RNase contamination and supplied with 10x Reaction Buffer.
DNase I Solution (10 mg/mL, 2000U Kunitz) is an endonuclease enzyme that hydrolyzes DNA into oligonucleotides and smaller fragments. It is commonly used to remove contaminating DNA from RNA preparations.
The enzyme provides high activity and reliability, making it suitable for molecular biology, RNA purification, and in vitro transcription workflows.
Have questions? Contact us
Price: 38.57 €
Detailed information:
Advantages & Features
- Recombinant bovine pancreatic DNase I, purified from E. coli (29 kDa).
- High specific activity: >2,000 Kunitz units per mg protein.
- High purity: RNase- and protease-free.
- Reliable performance in RNA workflows.
- Complete solution: supplied with optimized 10x Reaction Buffer.
Specifications
Unit definition:
One Kunitz unit is defined as the amount of enzyme required for the complete degradation of 1 µg of plasmid DNA in 10 minutes at 37 ˚C.
Note: One Kunitz unit equals to 50 Worthington units.
Includes
– 1 mL DNase I (10 mg/mL)
– 1 mL Reaction Buffer (10x)
* 10x Reaction Buffer: 100 mM Tris-HCl (pH 7.5 at 25°C), 25 mM MgCl2, 1 mM CaCl2
Download documentation
Datasheet MSDSApplications
- Removal of residual genomic DNA from RNA samples.
- Degradation of DNA template in transcription reactions.
- DNAse I footprinting assays.
- Nick translation protocols..
Tables & Figures
Quality Control
- Functionally tested for digestion of template DNA after in vitro transcription.
- Confirmed absence of RNAse activity.
- Specific activity assayed by degradation of 1 µg of pUC18 in 40 mM Tris‐HCl (pH 8.0), 10 mM MgSO4, 1 mM CaCl2.
Advice
Storage, Shipping & Guarantee
- Shipped in: Gel pack.
- Storage: -20 °C.
Citations
- Zhang, W., Li, L., Yang, G., Li, C., Deng, X., Huang, X., & Cheng, G. (2025). Investigating the Mechanism of β-Elemene-Mediated LINC00511 Modulation to Suppress Cisplatin Resistance in Lung Cancer. Journal of Visualized Experiments (JoVE), (222), e68825.
- Rozpędek-Kamińska, W., Piotrzkowska, D., Galita, G., Pytel, D., Kucharska, E., Dziki, Ł., … & Majsterek, I. (2022). Niskocząsteczkowe inhibitory zależnego od PERK szlaku sygnalizacyjnego adaptacyjnej odpowiedzi na stres w celowanej terapii raka jelita grubego. Polski Przegląd Chirurgiczny, 94(6).
- Beatriz, M., Vilaça, R., Anjo, S. I., Manadas, B., Januário, C., Rego, A. C., & Lopes, C. (2022). Defective mitochondrial-lysosomal axis promotes extracellular vesicles release of mitochondrial components in Huntington’s Disease. bioRxiv.
- Beatriz, M., Vilaça, R., Anjo, S. I., Manadas, B., Januário, C., Rego, A. C., & Lopes, C. (2022). Defective mitochondria‐lysosomal axis enhances the release of extracellular vesicles containing mitochondrial DNA and proteins in Huntington’s disease. Journal of Extracellular Biology, 1(10), e65.
Safety Statements
This product is developed, designed and sold exclusively for Research purposes and in vitro use only (RUO). The product was not tested for use in diagnostics or for drug development, nor is it suitable for administration to humans or animals. For more info, please check its Material Safety Data Sheet available in this website.
Customers Review
FAQs
